ClinicalTrials.gg
CompletedNCT00396006Updated May 13, 2021Results posted

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

A Phase 4 interventional study of Alpha1-Proteinase Inhibitor in Alpha 1-Antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.

Enrollment
15th of 25
21 · median 30
Started
2006
with 3 others
Phase 4
6 of 25
1 open now
Registered
5th of 25
by date
Lead sponsor
4 of 25
Baxalta now part of Shire

Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 15th largest by enrollment, is one of 4 that started in 2006, is one of 6 in phase 4, and was the 5th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alpha 1-Antitrypsin

alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of weekly augmentation therapy with ARALAST Fraction IV-1 (Fr IV-1) on epithelial lining fluid (ELF) alpha 1-proteinase inhibitor levels and other ELF analytes and to assess the safety of the treatment. Eligible subjects with a diagnosis of severe congenital alpha 1-antitrypsin deficiency will receive 8 consecutive weekly treatments with 60 mg/kg/week of functional ARALAST Fr IV-1 administered intravenously. The efficacy and safety assessments will include two bronchoscopies with bronchoalveolar lavage on study initiation and on study termination and multiple imaging and laboratory safety assessments. Each subject will participate for a minimum of 12 weeks.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated .
  • Male or female 18 years of age or older.
  • Documented, endogenous serum α1-PI level \< 40 mg/dL measured at screening (unless otherwise approved by the Sponsor) after a minimum of 28-day washout of any prior replacement therapy (if applicable).
  • Phenotype Pi Z (which includes Pi*Z/Z, Pi*Z/Null, or Pi*Malton/Z), or Pi*Null/Null.
  • Pulmonary functions at screening meeting the following criteria:

    1. Forced expiratory volume at 1 second () >= 50% of predicted value; or
    2. FEV1 > 35% of predicted value and diffusing capacity for carbon monoxide > 45% of predicated value, with no supplemental oxygen therapy and \< 3 pulmonary exacerbations or bronchitis requiring antibiotics/ within the past 12 months).
  • For any female of , a negative urine test for pregnancy within 7 days prior to the first bronchoalveolar lavage (BAL) visit and agreement to employ adequate measures for the duration of the study.
  • No abnormalities detected on a 12-lead (ECG) performed at the screening visit (ECG previously obtained within the past 12 months may be used, if available).
  • Laboratory results obtained at the screening visit, meeting the following criteria:

    1. Serum (ALT) \<= 2 times (ULN)
    2. Serum aspartate aminotransferase (AST) \<= 2 times ULN
    3. Serum total \<= 2 times ULN
    4. Proteinuria \< +2 on dipstick analysis
    5. Serum creatinine \<= 1.5 times ULN
    6. (ANC) >= 1500 cells/mm3
    7. (Hgb) >= 10.0 g/dL
    8. count >= 105/mm3
  • If the subject is treated with respiratory medications, such as inhaled bronchodilators or inhaled corticosteroids, or other chronic medications for the treatment of the subjects´s other medical condition(s), the subject's medication doses were unchanged for at least 14 days prior to the baseline BAL visit.

Exclusion criteria

Exclusion Criteria:

  • pulmonary impairment, other than chronic pulmonary disease ().
  • The subject has received any alpha 1 proteinase inhibitor (α1-PI) augmentation therapy (e.g., Prolastin, Zemaira, Aralast, or an α1-PI, by any route including intravenous and inhaled) within 28 days prior to screening.
  • The subject has received an investigational drug or device within 1 month prior to screening, or the subject is currently receiving an investigational drug or device. If the subject receives another investigational drug or device after enrollment, the subjects is to be withdrawn from the trial.
  • Presence of clinical symptoms of any lower respiratory tract infection or acute pulmonary exacerbation within 14 days prior to screening.
  • The subject has a known selective Immunoglobulin A (IgA) deficiency (IgA level less than 15 mg/dL) and/or antibody against IgA.
  • The subject is pregnant or lactating, or intends to become pregnant during the course of the study.
  • The subject is not a suitable candidate for a BAL procedure.
  • Moderate or severe bronchiectasis (total daily sputum production > 10 mL).
  • Clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance.
  • Prior history of adverse reaction to local anaesthetics, sedatives, pain control drugs, and other medication employed at the study center for perioperative care associated with the BAL procedure.
  • Long-term use of oral or parenteral glucocorticosteroid within 28 days prior to screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level

    Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  2. The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min

    Time frame: During 8 consecutive weeks of treatment

  3. Number of Changes in the Rate of Infusion

    Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min

    Time frame: During 8 consecutive weeks of treatment

Secondary outcomes

  1. Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels

    Median ratio of post- to pre-treatment BAL ELF ANEC levels

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  2. Change in in the Ratio of BAL ELF α1-PI to Human Neutrophil Elastase (HNE) Complex Concentration

    Median change in the ratio of BAL ELF α1-PI to HNE complex concentration from baseline to post-treatment

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  3. Change in the α1-PI Plasma Level

    Mean change in the plasma level of α1-PI from baseline to post-treatment

    Time frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment

  4. Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level

    Mean change in the plasma ANEC level from baseline to post-treatment

    Time frame: Blood samples were collected at baseline and after 8 consecutive weeks of treatment

  5. Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion

    Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: ≥ 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to \>38°C (\>100.4°F). If the pre-infusion body temperature was already \>38°C (\>100.4°F), then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant. • Respiratory rate: 25% increase above pre-infusion value

    Time frame: During 8 consecutive weeks of infusion

Other outcomes

  1. Change in the BAL ELF Free Neutrophil Elastase Level

    Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  2. Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level

    Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  3. Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level

    Median ratio of post- to pre-treatment BAL ELF IL-8 Level

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

  4. Change in the BAL ELF Tumor Necrosis Factor-alpha (TNF-α) From Baseline to Post-treatment

    Median change in the BAL ELF TNF-α from baseline to post-treatment

    Time frame: BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

07

Results

Posted Jan 4, 2011
Limitations and caveats
Isoelectric focusing (IEF) analyses that were intended to compare the profile of plasma α1-PI \& ELF α1-PI were not carried out due to fact that ELF samples were either missing, insufficient or too dilute for such assays.

Participant flow

Participants were recruited at 5 hospital sites in New Zealand and Australia. The period studied was 1 year and 2 months.

Participant flow — Overall Study
MilestoneParticipants Treated With ARALAST Fraction IV-1 (Fr. IV-1)
Started13
Completed13
Not completed0

Outcome measures

PrimaryChange in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level

Median change BAL ELF antigenic α1-PI level the from baseline to post-treatment

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Reported as:
Median · μM
Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level
μMPer Protocol
Change in Bronchoalveolar Lavage (BAL) Epithelial Lining Fluid (ELF) Alpha1-Proteinase Inhibitor (α1-PI) Level0.28 (-0.24 to 4.90)
Statistical analysis
  • Per Protocol · Wilcoxon signed rank test · p = 0.0195
PrimaryThe Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min
Time frame:
During 8 consecutive weeks of treatment
Reported as:
Number · adverse events
The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min
adverse eventsIntent to Treat
The Number of Adverse Events (AEs) Related to the Infusion of ARALAST Fr. IV 1 Administered at a Rate of 0.2 mL/kg/Min0
SecondaryRatio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels

Median ratio of post- to pre-treatment BAL ELF ANEC levels

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Reported as:
Median · μM
Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels
μMPer Protocol
Ratio of Post- to Pre-treatment BAL ELF Antineutrophil Elastase Capacity (ANEC) Levels1.22 (0.63 to 1.81)
SecondaryChange in in the Ratio of BAL ELF α1-PI to Human Neutrophil Elastase (HNE) Complex Concentration

Median change in the ratio of BAL ELF α1-PI to HNE complex concentration from baseline to post-treatment

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

No measurements were reported for this outcome.

SecondaryChange in the α1-PI Plasma Level

Mean change in the plasma level of α1-PI from baseline to post-treatment

Time frame:
Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Reported as:
Mean · μM
Change in the α1-PI Plasma Level
μMPer Protocol
Change in the α1-PI Plasma Level10.34 ± 2.50
Statistical analysis
  • Per Protocol · paired t-tests · p = <0.0001
SecondaryChange in the Plasma Antineutrophil Elastase Capacity (ANEC) Level

Mean change in the plasma ANEC level from baseline to post-treatment

Time frame:
Blood samples were collected at baseline and after 8 consecutive weeks of treatment
Reported as:
Mean · μM
Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level
μMPer Protocol
Change in the Plasma Antineutrophil Elastase Capacity (ANEC) Level9.46 ± 2.31
Statistical analysis
  • Per Protocol · paired t-tests · p = <0.0001
Other pre-specifiedChange in the BAL ELF Free Neutrophil Elastase Level

Median change in the BAL ELF Free Neutrophil Elastase Level from baseline to post-treatment

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Reported as:
Median · nM
Change in the BAL ELF Free Neutrophil Elastase Level
nMPer Protocol
Change in the BAL ELF Free Neutrophil Elastase Level41.17 (3.91 to 41.61)
Other pre-specifiedRatio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level

Median ratio of post- to pre-treatment BAL ELF Total Neutrophil Elastase Level

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Reported as:
Median · nM
Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level
nMPer Protocol
Ratio of Post- to Pre-treatment BAL ELF Total Neutrophil Elastase Level1.24 (0.47 to 30.97)
Statistical analysis
  • Per Protocol · Wilcoxon signed rank test · p = 0.1875
Other pre-specifiedRatio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level

Median ratio of post- to pre-treatment BAL ELF IL-8 Level

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)
Reported as:
Median · pg/mL
Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level
pg/mLPer Protocol
Ratio of Post- to Pre-treatment BAL ELF Interleukin 8 (IL-8) Level1.46 (0.48 to 10.38)
Statistical analysis
  • Per Protocol · Wilcoxon signed rank · p = 0.4375
Other pre-specifiedChange in the BAL ELF Tumor Necrosis Factor-alpha (TNF-α) From Baseline to Post-treatment

Median change in the BAL ELF TNF-α from baseline to post-treatment

Time frame:
BAL procedures were performed at baseline and after 8 consecutive weeks of treatment (minimum of 12 weeks)

No measurements were reported for this outcome.

PrimaryNumber of Changes in the Rate of Infusion

Number of decreases in the rate or discontinuations of infusion at 0.2 mL/kg/min

Time frame:
During 8 consecutive weeks of treatment
Reported as:
Number · infusions
Number of Changes in the Rate of Infusion
infusionsIntent to Treat
Number of Changes in the Rate of Infusion0
SecondaryClinically Significant Changes in Vital Signs From Pre- to Post-Infusion

Clinically significant changes in vital signs from pre- to post-infusion are: • Heart rate: 25% increase above pre-infusion value • Blood pressure: ≥ 30 mm Hg change from pre-infusion blood pressure (systolic or diastolic) • Temperature: an increase in body temperature to \>38°C (\>100.4°F). If the pre-infusion body temperature was already \>38°C (\>100.4°F), then any further increase in body temperature by 1.1°C (1.98°F) or more was considered clinically significant. • Respiratory rate: 25% increase above pre-infusion value

Time frame:
During 8 consecutive weeks of infusion
Reported as:
Number · # Clinically significant events
Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion
# Clinically significant eventsIntent to Treat
Clinically Significant Changes in Vital Signs From Pre- to Post-Infusion2

Adverse events

Collected over 1 year, 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intent to Treat—1/13 (7.7%)7/13 (53.8%)
Most frequent serious events
Most frequent serious events
EventIntent to Treat
Hepatitis A antibody positiveInvestigations1/13
Most frequent other events
Showing 10 of 13
Most frequent other events
EventIntent to Treat
SluggishnessGeneral disorders2/13
Post procedural complicationInjury, poisoning and procedural complications2/13
InflammationGeneral disorders1/13
Vessel puncture site haematomaGeneral disorders1/13
BronchitisInfections and infestations1/13
SinusitisInfections and infestations1/13
ContusionInjury, poisoning and procedural complications1/13
Blood pressure systolic abnormalInvestigations1/13
Respiratory rate increasedInvestigations1/13
Back painMusculoskeletal and connective tissue disorders1/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Participants Treated With ARALAST Fr. IV-1
<=18 years0
Between 18 and 65 years10
>=65 years3
Age, Continuous
Age, Continuous(years)Participants Treated With ARALAST Fr. IV-1
Median59.6 (36.0 to 76.1)
Sex: Female, Male
Sex: Female, Male(Participants)Participants Treated With ARALAST Fr. IV-1
Female6
Male7
Region of Enrollment
Region of Enrollment(Participants)Participants Treated With ARALAST Fr. IV-1
Australia8
New Zealand5
08

Study locations

5 sites
  • Adelaide, South Australia, Australia
  • Melbourne, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Otahuhu, Auckland, New Zealand
  • Hamilton, New Zealand
09

References and documents

Publications

  • Li Z, Franke RM, Morris DN, Yel L. Pharmacokinetics and Biochemical Efficacy of an alpha1-Proteinase Inhibitor (Aralast NP) in alpha1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. Pulm Ther. 2022 Sep;8(3):311-326. doi: 10.1007/s41030-022-00199-4. Epub 2022 Aug 24. PubMed 36001294 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2006 to primary completion in Dec 2007, 13 months.

Results were first posted in Jan 2011, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2006
First posted
Nov 6, 2006
StartActual
Oct 27, 2006
Primary completionActual
Dec 14, 2007
CompletionActual
Dec 14, 2007
Results first posted
Jan 4, 2011
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00396006
Responsible party
Sponsor
First posted
Nov 6, 2006
Start date
Oct 27, 2006
Primary completion
Dec 14, 2007
Completion
Dec 14, 2007
Results posted
Jan 4, 2011
Last update
May 13, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion